ILB-2201

N/A

Report date: 2024/11/15 15:13:15

Base Information

Drug NameILB-2201
Drug Alias NameILB-2201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsProgrammed death-ligand 1 blockers
TargetsVascular endothelial growth factorProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnolake Biopharm (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnolake Biopharm (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A